Quontdetect develops OTS-Probes and OTS-Assay, diagnostic tools that track circulating tumor DNA (ctDNA) from blood samples to provide personalized genomic testing for cancer patients. This technology enables precise evaluation of post-therapeutic lesions and early detection of cancer recurrence, enhancing treatment navigation for medical professionals.
Funding
$290K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Personalized genomic testing for cancer patients is often hindered by the challenge of tracking circulating tumor DNA (ctDNA) from blood samples, which requires highly sensitive and specific diagnostic tools. Current methods may lack the precision needed for accurate evaluation of post-therapeutic lesions and early detection of cancer recurrence.
Solution
Quontdetect has developed OTS-Probes and OTS-Assay, a suite of diagnostic tools designed for personalized cancer treatment navigation through the precise tracking of ctDNA in blood samples. OTS-Assay employs patient-specific probes to evaluate post-treatment lesions and detect early cancer recurrence with enhanced accuracy. The core of the technology lies in OTS (Off-The-Shelf) Probes, a library of digital PCR (dPCR) reagents that enable ultra-sensitive detection of genetic mutations. By targeting frequently detected mutations, Quontdetect aims to provide medical professionals with a new level of precision in genomic testing, facilitating more informed treatment decisions and improved patient outcomes.
Target Audience
The primary audience includes medical professionals, oncologists, and researchers focused on personalized cancer treatment and early detection of recurrence.
Features
- OTS-Assay: A personalized genomic test that tracks cancer-derived DNA in blood samples using patient-specific probes.
- OTS-Probes: A library of pre-designed dPCR probes for ultra-sensitive detection of frequently occurring cancer mutations.
- Early recurrence prediction: ctDNA levels rise earlier than with currently used methods.
- Treatment effect monitoring: Enables objective evaluation of treatment response to anticancer drugs and radiation therapy.
- Recurrence confirmation: If no ctDNA is detected with the probes, the chance of recurrence is low.
- Applicable to almost all cancers where genetic mutations are detected.